CRISPR Therapeutics Makes Board Changes
This article was originally published in Scrip
Executive Summary
CRISPR Therapeutics has appointed Pablo J. Cagnoni to its board of directors and Tony Coles will succeed Bradley Bolzon as chair. Cagnoni previously served as managing director of MPM Capital and is currently president and CEO of Tizona Therapeutics and executive chair of Blade Therapeutics.